Virtue Capital Management
VRTX icon

Virtue Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Virtue Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-455
Closed -$226K – 439
2026
Q2 		$226K Sell
455
-66
-13% -$29.2K 0.03% 324
2026
Q1 		$231K Sell
521
-8
-2% -$3.73K 0.04% 294
2025
Q4 		$239K Buy
+529
New +$228K 0.04% 273
2020
Q4 		– Sell
-9,962
Closed -$2.71M – 273
2020
Q3 		$2.71M Sell
9,962
-3,695
-27% -$1.02M 0.67% 32
2020
Q2 		$3.96M Buy
+13,657
New +$3.7M 0.91% 19
2020
Q1 		– Sell
-2,079
Closed -$455K – 208
2019
Q4 		$455K Sell
2,079
-13,241
-86% -$2.68M 0.13% 156
2019
Q3 		$2.6M Sell
15,320
-2,168
-12% -$384K 0.86% 38
2019
Q2 		$3.21M Buy
+17,488
New +$3.06M 1.17% 22
2018
Q4 		– Sell
-25,630
Closed -$4.94M – 232
2018
Q3 		$4.94M Buy
25,630
+15,176
+145% +$2.7M 1.04% 15
2018
Q2 		$1.78M Buy
10,454
+4,201
+67% +$651K 0.86% 22
2018
Q1 		$992K Buy
6,253
+3,198
+105% +$522K 0.52% 48
2017
Q4 		$458K Buy
+3,055
New +$452K 0.26% 106

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Virtue Capital Management's VRTX Position: Q3 2026 in Review

Virtue Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 455 shares — an estimated $226K sold.

Virtue Capital Management first reported a position in VRTX in Q4 2017 and held it in 12 quarters. The position peaked at $4.94M in Q3 2018. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Virtue Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Virtue Capital Management sold 455 Vertex Pharmaceuticals shares in Q3 2026, an estimated $226K.
  • Virtue Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 12 quarters.
  • Virtue Capital Management's Vertex Pharmaceuticals position peaked at $4.94M in Q3 2018.
  • 992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Virtue Capital Management's 13F filing for Q3 2026, filed 29 Oct 2026.